U.S. markets open in 1 hour 52 minutes

iShares MSCI India ETF (INDA)

BATS - BATS Delayed Price. Currency in USD
Add to watchlist
40.16-1.53 (-3.67%)
At close: 4:00PM EDT

40.40 +0.24 (0.60%)
Pre-Market: 6:38AM EDT

Full screen
Trade prices are not sourced from all markets
Previous Close41.69
Bid40.22 x 21500
Ask42.21 x 1100
Day's Range40.07 - 40.38
52 Week Range24.65 - 43.84
Avg. Volume3,976,925
Net Assets5.11B
PE Ratio (TTM)N/A
YTD Daily Total Return4.57%
Beta (5Y Monthly)0.98
Expense Ratio (net)0.69%
Inception Date2012-02-02
  • Revolution Medicines to Participate in Upcoming Investor Conferences

    Revolution Medicines to Participate in Upcoming Investor Conferences

    REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will deliver a corporate presentation at the Oppenheimer 31st Annual Healthcare Conference and be the featured speaker in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum. Details of these events are as follows: Oppenheimer 31st Annual Healthcare ConferenceConference Date: March 16-18, 2021Presentation Time/Date: 1:10 – 1:40 p.m. Eastern on Tuesday, March 16, 2021Format: Virtual conference J.P. Morgan 10th Annual Napa Valley ForumConference Date: March 29-31, 2021Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021Format: Virtual conference About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845. CONTACT: Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com

  • ETF Opens India Financials Door

    ETF Opens India Financials Door

    Emerging markets are heating up, and India could be poised for massive growth.